PTC Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
34,696.30
25,245.00
36,766.00
82,705.00
194,392.00
264,734
Cost of Goods Sold (COGS) incl. D&A
-
-
-
-
19,957.00
35,547
Gross Income
-
-
-
-
174,435.00
229,187
SG&A Expense
77,697.40
122,423.00
201,020.00
208,973.00
238,727.00
323,832
EBIT
45,397.50
99,413.00
-
129,558.00
64,292.00
94,645
Unusual Expense
92.50
130.00
140.00
2,453.00
-
21,040
Non Operating Income/Expense
-
83.00
605.00
1,254.00
1,279.00
129
Interest Expense
6,083.70
-
2,367.00
8,276.00
12,094.00
12,554
Pretax Income
51,573.60
98,446.00
169,962.00
141,541.00
77,665.00
128,110
Income Tax
-
4,693.00
485.00
569.00
1,335.00
29
Consolidated Net Income
48,182.80
93,753.00
170,447.00
142,110.00
79,000.00
128,081
Net Income
48,182.80
93,753.00
170,447.00
142,110.00
79,000.00
128,081
Net Income After Extraordinaries
48,182.80
93,753.00
170,447.00
142,110.00
79,000.00
128,081
Net Income Available to Common
66,431.60
93,753.00
170,447.00
142,110.00
79,000.00
128,081
EPS (Basic)
5.18
2.97
5.07
4.17
2.02
2.75
Basic Shares Outstanding
12,829.40
31,565.30
33,626.20
34,044.60
39,183.10
46,576.30
EPS (Diluted)
5.18
2.97
5.07
4.17
2.02
2.75
Diluted Shares Outstanding
12,829.40
31,565.30
33,626.20
34,044.60
39,183.10
46,576.30
EBITDA
43,001.10
97,178.00
164,254.00
126,268.00
46,610.00
68,558
Non-Operating Interest Income
-
1,180.00
-
-
-
-
Other After Tax Income (Expense)
3,390.80
-
-
-
-
-
Preferred Dividends
18,248.80
-
-
-
-
-
About PTC Therapeutics
View Profile
